IBDEI0CD ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5876,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5876,1,4,0)
 ;;=4^V19.2
 ;;^UTILITY(U,$J,358.3,5876,1,5,0)
 ;;=5^Family h/o Deafness Or Hearing Loss
 ;;^UTILITY(U,$J,358.3,5876,2)
 ;;=^295322
 ;;^UTILITY(U,$J,358.3,5877,0)
 ;;=V17.3^^41^491^16
 ;;^UTILITY(U,$J,358.3,5877,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5877,1,4,0)
 ;;=4^V17.3
 ;;^UTILITY(U,$J,358.3,5877,1,5,0)
 ;;=5^Family h/o Ischemic Heart Dis
 ;;^UTILITY(U,$J,358.3,5877,2)
 ;;=^295305
 ;;^UTILITY(U,$J,358.3,5878,0)
 ;;=V16.6^^41^491^17
 ;;^UTILITY(U,$J,358.3,5878,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5878,1,4,0)
 ;;=4^V16.6
 ;;^UTILITY(U,$J,358.3,5878,1,5,0)
 ;;=5^Family h/o Leukemia
 ;;^UTILITY(U,$J,358.3,5878,2)
 ;;=^295298
 ;;^UTILITY(U,$J,358.3,5879,0)
 ;;=V18.61^^41^491^19
 ;;^UTILITY(U,$J,358.3,5879,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5879,1,4,0)
 ;;=4^V18.61
 ;;^UTILITY(U,$J,358.3,5879,1,5,0)
 ;;=5^Family h/o Polycystic Kidney
 ;;^UTILITY(U,$J,358.3,5879,2)
 ;;=^321531
 ;;^UTILITY(U,$J,358.3,5880,0)
 ;;=V17.0^^41^491^20
 ;;^UTILITY(U,$J,358.3,5880,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5880,1,4,0)
 ;;=4^V17.0
 ;;^UTILITY(U,$J,358.3,5880,1,5,0)
 ;;=5^Family h/o Psychiatric Condition
 ;;^UTILITY(U,$J,358.3,5880,2)
 ;;=^295302
 ;;^UTILITY(U,$J,358.3,5881,0)
 ;;=V19.4^^41^491^21
 ;;^UTILITY(U,$J,358.3,5881,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5881,1,4,0)
 ;;=4^V19.4
 ;;^UTILITY(U,$J,358.3,5881,1,5,0)
 ;;=5^Family h/o Skin Condition
 ;;^UTILITY(U,$J,358.3,5881,2)
 ;;=^295324
 ;;^UTILITY(U,$J,358.3,5882,0)
 ;;=V17.1^^41^491^22
 ;;^UTILITY(U,$J,358.3,5882,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5882,1,4,0)
 ;;=4^V17.1
 ;;^UTILITY(U,$J,358.3,5882,1,5,0)
 ;;=5^Family h/o Stroke (CVA)
 ;;^UTILITY(U,$J,358.3,5882,2)
 ;;=^295303
 ;;^UTILITY(U,$J,358.3,5883,0)
 ;;=V16.8^^41^491^12
 ;;^UTILITY(U,$J,358.3,5883,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5883,1,4,0)
 ;;=4^V16.8
 ;;^UTILITY(U,$J,358.3,5883,1,5,0)
 ;;=5^Family h/o Cancer,Other Specified
 ;;^UTILITY(U,$J,358.3,5883,2)
 ;;=^295300
 ;;^UTILITY(U,$J,358.3,5884,0)
 ;;=V11.1^^41^491^24
 ;;^UTILITY(U,$J,358.3,5884,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5884,1,4,0)
 ;;=4^V11.1
 ;;^UTILITY(U,$J,358.3,5884,1,5,0)
 ;;=5^Hx of Affective Disorder
 ;;^UTILITY(U,$J,358.3,5884,2)
 ;;=^295250
 ;;^UTILITY(U,$J,358.3,5885,0)
 ;;=V15.89^^41^491^46
 ;;^UTILITY(U,$J,358.3,5885,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5885,1,4,0)
 ;;=4^V15.89
 ;;^UTILITY(U,$J,358.3,5885,1,5,0)
 ;;=5^Hx of Persian Gulf Region Exposure
 ;;^UTILITY(U,$J,358.3,5885,2)
 ;;=^295291
 ;;^UTILITY(U,$J,358.3,5886,0)
 ;;=V11.3^^41^491^25
 ;;^UTILITY(U,$J,358.3,5886,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5886,1,4,0)
 ;;=4^V11.3
 ;;^UTILITY(U,$J,358.3,5886,1,5,0)
 ;;=5^Hx of Alcoholism
 ;;^UTILITY(U,$J,358.3,5886,2)
 ;;=^295252
 ;;^UTILITY(U,$J,358.3,5887,0)
 ;;=V15.07^^41^491^26
 ;;^UTILITY(U,$J,358.3,5887,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5887,1,4,0)
 ;;=4^V15.07
 ;;^UTILITY(U,$J,358.3,5887,1,5,0)
 ;;=5^Hx of Allergy to Latex
 ;;^UTILITY(U,$J,358.3,5887,2)
 ;;=^322043
 ;;^UTILITY(U,$J,358.3,5888,0)
 ;;=V13.4^^41^491^27
 ;;^UTILITY(U,$J,358.3,5888,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5888,1,4,0)
 ;;=4^V13.4
 ;;^UTILITY(U,$J,358.3,5888,1,5,0)
 ;;=5^Hx of Arthritis
 ;;^UTILITY(U,$J,358.3,5888,2)
 ;;=^295267
 ;;^UTILITY(U,$J,358.3,5889,0)
 ;;=V12.72^^41^491^31
 ;;^UTILITY(U,$J,358.3,5889,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5889,1,4,0)
 ;;=4^V12.72
 ;;^UTILITY(U,$J,358.3,5889,1,5,0)
 ;;=5^Hx of Colon Polyps
 ;;^UTILITY(U,$J,358.3,5889,2)
 ;;=^303401
